We exploit dislocations in markets and unlock value from complex situations using a Get Rich and Stay Rich strategy. This strategy has given rise to returns over 23 years of 28% p.a. Net IRR
Brooklyn ImmunoTherapeutics’ Board of Directors announce new Senior Management hires
Brooklyn ImmunoTherapeutics, a clinical-stage company developing novel immunotherapies focused on reducing immune suppression seen in the cancer tumour micro-environment, has announced two major hires in the senior management team.
Mark Leuchtenberger has been appointed as President, Chief Executive Officer and Director, while Monil Shah takes the position of Chief Operating Officer. One of the first tasks of the new President, CEO and Director was to present at the BioCentury 24th Annual Future Leaders in the Biotech Industry Conference in New York City on April 7th, 2017. Previous CEO and founder of IRX John W. Hadden II will continue as Director.
Mr. Leuchtenberger brings 20 years of experience as a senior executive in the biopharmaceutical industry where he has led companied through private financings and initial public offerings, taken products from IND through to commercialization and achieved M&A exits. He has served as President and Chief Executive Officer of companies such as Chiasma, Acusphere, Inc., and Rib-X Pharmaceuticals, Inc. (now Melinta Therapeutics Inc.). Mr. Leuchtenberger served as President and Chief Executive Officer of Targanta Therapeutics Corporation, where he led the company’s initial public offering in 2007 and its acquisition by The Medicines Company in 2009. Mr. Leuchtenberger served as the President and Chief Executive Officer of cancer vaccine company, Therion Biologics Corporation.
Dr. Shah brings a similar wealth of experience through 17 years of pharmaceutical and biotechnology industry experience in Oncology drug development, including Clinical Research and Development and Medical Affairs. Most recently, Dr. Shah was the Medical Affairs Lead for Immuno-Oncology at Bristol Myers Squibb. Dr. Shah helped start a biotech company as the Head of Clinical Operations and Development at Ventrus Biosciences. Prior to Ventrus, Dr. Shah led the solid tumour development programs and was eventually offered the opportunity to lead the clinical portfolio and strategic planning function at Celgene Corporation.
For more information on Brooklyn ImmunoTherapeutics, see https://www.brooklynitx.com/
Pension Insurance Corporation Group Limited (“PICG” or the “Company”), ultimate parent company of Pension Insurance Corporation plc (“PIC”), the specialist insurer of defined benefit pension schemes, today announces its final results for the 12 months to 31 December 2021.
The Pension SuperFund (“PSF”) today announces the appointment of Michael Clark as its Chief Executive Officer (“CEO”). Michael joins PSF from Shell where he has been Global Head of Pensions, responsible for the governance and administration of all the Group’s pension arrangements.
Telent has announced that it has acquired the Harlequin Group, a specialist technology services company. Complementing Telent’s existing business operations, building telecom infrastructure for mobile network operators (MNO) and service providers, the acquisition significantly enhances its professional services capability in the site acquisition and design arena.
London, 4 October 2021 – Pension Insurance Corporation plc (“PIC”), a specialist insurer of defined benefit pension funds, has signed a £2.2 billion pension insurance buy-in with the Trustee of the Metal Box Pension Scheme...
The Pension Superfund has announced the makeup of its asset and liability management (ALM) committee – unveiling names including Aberdeen Standard Investments chairman Martin Gilbert and former Railpen chief executive Chris Hitchen as part of its team...
As Armed Forces Day on 26th June fast-approaches, Telent remains committed to helping service leavers transition successfully out of the forces and thrive in the next chapter of their lives.